Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS‐CoV‐2 Variants: A Case Report Study with Comparison to a Vaccinated Population

• Published in: Case reports in infectious diseases Vol. 2024; no. 1; p. 9163490
• Main Authors: Gillot, Constant, Bayart, Jean-Louis, Maloteau, Vincent, Dogné, Jean-Michel, Douxfils, Jonathan, Favresse, Julien
• Format: Journal Article
• Language: English
• Published: Egypt John Wiley & Sons, Inc 2024; Wiley
• Subjects: Antibodies; Case Report; Case reports; Cell culture; COVID-19 vaccines; Electronic components industry; Health aspects; Monoclonal antibodies; Patients; Pharmaceutical industry; Proteins; Severe acute respiratory syndrome coronavirus 2; Vaccination; Viral antibodies; Belgium; United States; United Kingdom; United States > US

AZD7442 (150 mg of tixagevimab plus 150 mg of cilgavimab) has been approved for the preexposure prophylaxis of COVID‐19 and for the treatment of adults and adolescents with COVID‐19 who do not require supplemental oxygen and who are at increased risk of severe COVID‐19. Thus, the aim of the present...